SCHEMBL3473194

SCHEMBL3473194

CC(=O)Nc1ccccc1-c1ccc(-c2cc(C(C)(C)O)nn2-c2ccccc2Cl)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 6/20 0.60
NR1H2 P55055 6/20 0.60
NR1H3 Q13133 6/20 0.60
MAPK14 Q16539 2/20 0.38
NTRK1 P04629 1/20 0.36
SLC16A3 O15427 3/20 0.35
SLC16A1 P53985 3/20 0.35
P2RY1 P47900 1/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
STIM1 Q13586 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3471847 0.93 RXRA (0.60) RXRANR1H2NR1H3MAPK14SLC16A3
SCHEMBL15690866 0.89 RXRA (0.56) RXRANR1H2NR1H3MAPK14SLC16A3
SCHEMBL3472653 0.87 RXRA (0.68) RXRANR1H2NR1H3MAPK14SLC16A3
SCHEMBL3473467 0.85 RXRA (0.63) RXRANR1H2NR1H3SLC16A3SLC16A1
SCHEMBL3471422 0.85 RXRA (0.68) RXRANR1H2NR1H3MAPK14P2RY1
SCHEMBL3471716 0.84 RXRA (0.69) RXRANR1H2NR1H3KDM4ENPC1
SCHEMBL14624244 0.84 RXRA (0.57) RXRANR1H2NR1H3MAPK14SLC16A3
SCHEMBL3472294 0.83 RXRA (0.64) RXRANR1H2NR1H3SLC16A3SLC16A1
SCHEMBL3473365 0.83 RXRA (0.67) RXRANR1H2NR1H3MAPK14SLC16A3
SCHEMBL3472047 0.83 RXRA (0.60) RXRANR1H2NR1H3SLC16A3SLC16A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.